MedTrace Logo

APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

NCT03615235 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2025-12-15

No results posted yet for this study

Summary

The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes.

Conditions

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Barry I. Freedman, MD · Wake Forest University Health Sciences

  • David M. Reboussin, PhD · Wake Forest University Health Sciences

  • Paul L. Kimmel, MD · Natl Institute of Diabetes, Digestive & Kidney Diseases

  • Marva Moxey-Mims, MD · Children's Natl Health System; George Washington Univ Sch of Med and Health Serv

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-21
Primary Completion
2027-05-30
Completion
2027-05-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03615235 on ClinicalTrials.gov